JAN KOCH-WESER, M.D.; VICTOR W. SIDEL, M.D.; ELIZABETH B. FEDERMAN, R.N.; PAULA KANAREK, M.A.; DIANA C. FINER, B.A.; ANN E. EATON, M.Ed.
Two hundred and eighty-eight hospitalized patients were monitored during and after 317 courses of sodium colistimethate therapy to determine incidence and manifestations of adverse reactions. Adverse renal reactions occurred during 20.2% of colistin utilizations and were generally reversible. Acute tubular necrosis occurred during 1.9% of utilizations, manifestations of colistin neurotoxicity developed during 7.3%. Respiratory insufficiency and apnea were seen in 2.1% of patients. Adverse effects of colistin therapy contributed to the death of 13 (4.5%) patients. Adverse effects of colistin therapy contributed to the death of 13 (4.5%) patients treated with the drug. Sixty-four percent of adverse reactions to colistin became manifest during the first 4 days of therapy, and 95% occurred in patients who received no more than the recommended dose. For any given mean daily dose per pound, reaction rates increased markedly with patient weight. Colistin dosage proportional to the square root of patient weight might avoid the excess reaction rate in heavy patients and produce more effective blood levels in light patients.
KOCH-WESER J, SIDEL VW, FEDERMAN EB, KANAREK P, FINER DC, EATON AE. Adverse Effects of Sodium Colistimethate: Manifestations and Specific Reaction Rates During 317 Courses of Therapy. Ann Intern Med. ;72:857–868. doi: 10.7326/0003-4819-72-6-857
Download citation file:
Published: Ann Intern Med. 1970;72(6):857-868.
Hospital Medicine, Prevention/Screening, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use